Biocon, a biotechnology firm, has partnered with Brazil’s Biomm SA to introduce its diabetes drug in Latin America. Biocon will handle development, manufacturing, and supply of Semaglutide (gOzempic), while Biomm will secure regulatory approval and oversee commercialization in Brazil. Biomm specializes in developing, manufacturing, and commercializing biotech and biosimilar drug products at its Nova Lima facility. Biocon’s CEO and MD, Siddharth Mittal, views this partnership as a significant step in their global expansion strategy for Peptides, extending beyond the US and Europe